253 related articles for article (PubMed ID: 35779497)
1. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
2. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
3. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
Mehta P; Bothiraja C; Kadam S; Pawar A
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
[TBL] [Abstract][Full Text] [Related]
4. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
ElKasabgy NA; Adel IM; Elmeligy MF
AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
[TBL] [Abstract][Full Text] [Related]
9. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
10. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
12. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
[TBL] [Abstract][Full Text] [Related]
13. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
14. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
[TBL] [Abstract][Full Text] [Related]
15. The quest to deliver high-dose rifampicin: can the inhaled approach help?
Khadka P; Dummer J; Hill PC; Das SC
Expert Opin Drug Deliv; 2024; 21(1):31-44. PubMed ID: 38180078
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
17. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
Srichana T; Eze FN; Thawithong E
Drug Dev Ind Pharm; 2022 Oct; 48(10):528-538. PubMed ID: 36214588
[TBL] [Abstract][Full Text] [Related]
18. Uniformity and Efficacy of Dry Powders Delivered to the Lungs of a Mycobacterial-Surrogate Rat Model of Tuberculosis.
Hirota K; Hirai Y; Nakajima T; Goto S; Makino K; Terada H
Pharm Res; 2022 Jan; 39(1):143-152. PubMed ID: 34950976
[TBL] [Abstract][Full Text] [Related]
19. An Overview of Recently Published Patents on Pulmonary Drug Delivery Devices.
Dongare SL; Narkhede MR
Recent Adv Drug Deliv Formul; 2023 Apr; ():. PubMed ID: 37185326
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
Willis L; Hayes D; Mansour HM
Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
